| Authored | 1 |
| Substantive (25+ words) | 1 |
| Threads posted in | 1 |
| Distinct active days | 1 |
| Words authored | 323 |
| Received (incl. group broadcast) | 2 |
Received counts include every message sent to a channel this person belonged to. That measures presence, not participation.
2 sentences were extracted and attributed to this person. Most are not their own opinion. Reporting the total as “2 statements” would misrepresent them.
| Person | Medium | Msgs | Span |
|---|---|---|---|
| George Korch | 2 | 2010-01-19 – 2010-01-19 | |
| Anthony S. Fauci | 1 | 2010-01-19 – 2010-01-19 | |
| Dan Sosin | 1 | 2010-01-19 – 2010-01-19 | |
| Gerald Parker | 1 | 2010-01-19 – 2010-01-19 | |
| Margaret A Hamburg | 1 | 2010-01-19 – 2010-01-19 | |
| Michael Kurilla | 1 | 2010-01-19 – 2010-01-19 | |
| Rima Khabbaz | 1 | 2010-01-19 – 2010-01-19 | |
| Robin Robinson | 1 | 2010-01-19 – 2010-01-19 | |
| Thomas Frieden | 1 | 2010-01-19 – 2010-01-19 |
Showing: own voice, substantive needs context quoted / not their view all
I understand here we are talking about both multipathogen (e.g. broadly acting antimicrobials or, as in flu example, vaccines) and platform technologies that could be generalized to multiple pathogens or threats.
Reading Room Production, p.439 · original PDF · in context
Issues with focusing too much attention on "broad spectrum" in terms of broad activity may include the following - a) that such accomplishments may be difficult to achieve scientifically and b) that we will face the challenge we face with tiuse and uum that can commercially usable drugs, the tension between broad use leading to resistance development, vs.. preserving for resistance and MCM needs.
Reading Room Production, p.439 · original PDF · in context